6,7-Bis-(4-methoxy-phenyl)-1-methyl-2,2-dioxo-1,2-dihydro-2λ⁶-pyrazino[2,3-c][1,2,6]thiadiazin-4-ylamine | 126684-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6,7-Bis-(4-methoxy-phenyl)-1-methyl-2,2-dioxo-1,2-dihydro-2λ⁶-pyrazino[2,3-c][1,2,6]thiadiazin-4-ylamine
• 英文别名: 6,7-Bis(4-methoxyphenyl)-1-methyl-2,2-dioxo-pyrazino[2,3-c][1,2,6]thiadiazin-4-imine；6,7-bis(4-methoxyphenyl)-1-methyl-2,2-dioxopyrazino[2,3-c][1,2,6]thiadiazin-4-amine
• CAS: 126684-50-2
• 化学式: C₂₀H₁₉N₅O₄S
• 分子量: 425.468
• InChiKey: GPRRHLKURLZYPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  6,7-Bis-(4-methoxy-phenyl)-1-methyl-2,2-dioxo-1,2-dihydro-2λ⁶-pyrazino[2,3-c][1,2,6]thiadiazin-4-ylamine 在 tetraphosphorus decasulfide 、 potassium carbonate 作用下， 以 吡啶 、 甲醇 、 水 为溶剂， 反应 50.0h， 生成 1-methyl-7-phenyl-1H-pyrazino[2,3-c][1,2,6]thiadiazin-4(3H)-thione 2,2-dioxide
  参考文献：
  名称：

  关于1 H-吡嗪并[2,3- c ] [1,2,6]噻二嗪2,2-二氧化物及其衍生物的反应性：亲核取代，胺化，醛醇缩合，氧化和水解

  摘要：

  研究了与蝶啶结构相关的1 H-吡嗪并[2,3- c ] [1,2,6]噻二嗪2,2-二氧化物体系的反应活性，并合成了许多新颖的衍生物。比较了这两个相关的熔融聚氮杂体系的化学行为。

  DOI：

  10.1002/hlca.200390003
• 作为产物：
  描述：

  4,4'-二甲氧基苯酚酯 在 盐酸 、 三乙胺 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 96.0h， 生成 6,7-Bis-(4-methoxy-phenyl)-1-methyl-2,2-dioxo-1,2-dihydro-2λ⁶-pyrazino[2,3-c][1,2,6]thiadiazin-4-ylamine
  参考文献：
  名称：

  Novel Arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-Dioxides as Platelet Aggregation Inhibitors. 2. Optimization by Quantitative Structure−Activity Relationships

  摘要：

  In the previous paper (Part 1), we described the synthesis and antiplatelet activity of a series of phenyl- and heteroarylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. In this paper, we report the optimization of the platelet aggregation inhibitory activity by an iterative sequence of quantitative structure-activity relationship studies which encompassed synthesis and evaluation of the effects of structure variations at the 1-, 6-, and 7-positions of the heterocyclic system. A model has been established that correctly correlates antiplatelet activity in this series with the partial atomic charges calculated by a local density functional ab initio method. As a result of this study, the experimental platelet aggregation inhibitory activity of the lead compound was improved 300-fold.

  DOI：

  10.1021/jm981104b

文献信息

• HERRERO, A.;OCHOA, C.;STUD, Y. M., AN. REAL ACAD. FARM., 55,(1989) N, C. 451-459
  作者：HERRERO, A.、OCHOA, C.、STUD, Y. M.

  DOI：——

  日期：——
• On the Reactivity of 1H-Pyrazino[2,3-c][1,2,6]thiadiazine 2,2-Dioxide and Derivatives: Nucleophilic Substitution, Amination, Aldol-Type Condensation, Oxidation, and Hydrolysis
  作者：Nuria Campillo、Juan Antonio Páez、Pilar Goya

  DOI：10.1002/hlca.200390003

  日期：2003.1

  The reactivity of the 1H-pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide system, structurally related to pteridine, was studied, and a number of novel derivatives were synthesized. The chemical behaviors of these two related fused polyaza systems were compared.

  研究了与蝶啶结构相关的1 H-吡嗪并[2,3- c ] [1,2,6]噻二嗪2,2-二氧化物体系的反应活性，并合成了许多新颖的衍生物。比较了这两个相关的熔融聚氮杂体系的化学行为。
• Novel Arylpyrazino[2,3-<i>c</i>][1,2,6]thiadiazine 2,2-Dioxides as Platelet Aggregation Inhibitors. 2. Optimization by Quantitative Structure−Activity Relationships
  作者：Nuria Campillo、Pilar Goya、Juan A. Páez

  DOI：10.1021/jm981104b

  日期：1999.8.1

  In the previous paper (Part 1), we described the synthesis and antiplatelet activity of a series of phenyl- and heteroarylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. In this paper, we report the optimization of the platelet aggregation inhibitory activity by an iterative sequence of quantitative structure-activity relationship studies which encompassed synthesis and evaluation of the effects of structure variations at the 1-, 6-, and 7-positions of the heterocyclic system. A model has been established that correctly correlates antiplatelet activity in this series with the partial atomic charges calculated by a local density functional ab initio method. As a result of this study, the experimental platelet aggregation inhibitory activity of the lead compound was improved 300-fold.